In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Anti-Bacterial Agents
/ pharmacology
Azabicyclo Compounds
/ pharmacology
Borinic Acids
/ pharmacology
Boronic Acids
/ pharmacology
Carboxylic Acids
/ pharmacology
Cefepime
/ pharmacology
Ceftazidime
/ pharmacology
Drug Combinations
Drug Therapy, Combination
Heterocyclic Compounds, 1-Ring
/ pharmacology
Humans
Klebsiella pneumoniae
/ drug effects
Meropenem
/ pharmacology
Microbial Sensitivity Tests
Pseudomonas aeruginosa
/ drug effects
beta-Lactamase Inhibitors
/ pharmacology
beta-Lactamases
/ genetics
K. pneumoniae
P. aeruginosa
beta-lactamase inhibitor
metallo-beta-lactamase-producing isolates
Journal
International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
24
05
2021
revised:
28
08
2021
accepted:
12
09
2021
pubmed:
23
9
2021
medline:
27
1
2022
entrez:
22
9
2021
Statut:
ppublish
Résumé
Metallo-beta-lactamase (MBL)-producing Gram-negative bacteria are increasing worldwide and very few agents are active against these pathogens. Taniborbactam (formerly VNRX-5133) is a newly developed bicyclic boronate beta-lactamase inhibitor that directly inhibits all four Ambler classes of beta-lactamases. In the present study the in vitro activity of cefepime or meropenem combined with taniborbactam against 100 Klebsiella pneumoniae and cefepime combined with taniborbactam against 100 Pseudomonas aeruginosa molecularly characterized MBL-producing strains were investigated using ISO standard broth microdilution assays and compared with a panel of antimicrobial agents that are used in clinical practice (amikacin, aztreonam, ciprofloxacin, levofloxacin, gentamicin, piperacillin/tazobactam, imipenem, tigecycline, ceftolozane-tazobactam, cefepime-tazobactam, meropenem-vaborbactam, ceftazidime-avibactam). For K. pneumoniae isolates, the MIC
Identifiants
pubmed: 34551356
pii: S0924-8579(21)00721-4
doi: 10.1016/j.ijantimicag.2021.106440
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azabicyclo Compounds
0
Borinic Acids
0
Boronic Acids
0
Carboxylic Acids
0
Drug Combinations
0
Heterocyclic Compounds, 1-Ring
0
avibactam, ceftazidime drug combination
0
beta-Lactamase Inhibitors
0
meropenem and vaborbactam
0
Cefepime
807PW4VQE3
taniborbactam
8IGQ156Z07
Ceftazidime
9M416Z9QNR
beta-Lactamases
EC 3.5.2.6
Meropenem
FV9J3JU8B1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106440Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.